1. Home
  2. AGMH vs MBIO Comparison

AGMH vs MBIO Comparison

Compare AGMH & MBIO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AGMH

AGM Group Holdings Inc.

HOLD

Current Price

$0.80

Market Cap

5.0M

Sector

Technology

ML Signal

HOLD

MBIO

Mustang Bio Inc.

HOLD

Current Price

$0.54

Market Cap

4.1M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
AGMH
MBIO
Founded
2015
2015
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
5.0M
4.1M
IPO Year
2017
2023

Fundamental Metrics

Financial Performance
Metric
AGMH
MBIO
Price
$0.80
$0.54
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
771.4K
20.1K
Earning Date
05-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
98.99
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.07
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.48
$0.47
52 Week High
$11.74
$1.84

Technical Indicators

Market Signals
Indicator
AGMH
MBIO
Relative Strength Index (RSI) 42.27 40.08
Support Level N/A N/A
Resistance Level $1.18 $0.56
Average True Range (ATR) 0.15 0.03
MACD -0.01 -0.00
Stochastic Oscillator 34.58 50.52

Price Performance

Historical Comparison
AGMH
MBIO

About AGMH AGM Group Holdings Inc.

AGM Group Holdings Inc is a technology company engaged in technology hardware research and development, manufacturing, assembly, and sales. Its core business segments include research and development of blockchain-oriented ASIC chips, production of high-end crypto miners for Bitcoin and other cryptocurrencies, and Fintech software services. The Company mainly derives revenue from the sales of cryptocurrency mining machines and standardized computing equipment.

About MBIO Mustang Bio Inc.

Mustang Bio Inc is a clinical-stage biopharmaceutical company focused on translating today's medical breakthroughs into potential cures for difficult-to-treat cancers. It acquires rights to these technologies by licensing or otherwise acquiring an ownership interest in the technologies, funding their research and development, and eventually either out-licensing or bringing the technologies to market. Its pipeline is currently focused on the core areas of gene therapies for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors.

Share on Social Networks: